EMVision (ASX:EMV) make a stroke care breakthrough
August 22, 2023EMVision Medical Devices’ initial imaging case studies have confirmed a 100 per cent scan success rate in producing processable signals using the company’s novel and advanced AI-powered probabilistic imagining technique to identify stroke types.
Rapid diagnosis is critical to preserve brain matter after a suspected stroke, and EMVision is developing a first of its kind bedside electromagnetic imaging device which can rapidly deliver an image – with early trials now showing the mean time for completing a full workflow and brain scan at 9.2 minutes.
Principal investigator at Liverpool Hospital Dr Dennis Cortado said that it was an exciting development in stroke and neurological care.
“We have found the EMVision scanner to be a very user-friendly portable imaging modality. The EMVision scanner has the potential for wide application in both the prehospital and acute hospital settings,” Dr Cortado said.
EMVision Chief Executive and Managing Director Scott Kirkland said that the team was achieving significant breakthroughs with its first-generation product over the year, made possible with talented engineers, proprietary simulation data pipeline alongside latest advancements in high performance computing and AI.
“As we progress through our studies, we are excited to learn about the full potential and capabilities of our world first technology and look forward to sharing further insights with the market,” Mr Kirkland said.
Path to development
It takes time to develop a novel and proprietary health care technology, but the results are certainly a breakthrough. No adverse effects using the device occurred, and the data and learnings will be key in further advancing the technology’s algorithm techniques.
With an initial round of testing completed, the techniques are now subject to further development and verifications, with the background anatomical reconstruction set to be combined with a separate series of algorithms to continue refining the ability to classify and localise stroke types.
EMVision’s caste studies will now be presented at ‘Stroke 2023’, the annual scientific meeting of the Stroke Society of Australasia and Smart Strokes, alongside an abstract printed in the International Journal of Stroke, the flagship publication of the World Stroke Organization.
Exemplar case studies
$1.96Please note the following valuable information before using this website.
Independent Research
Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.
